Literature DB >> 27903668

Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment.

Anna C Bibby1,2, Selina Tsim3,4, Nikolaos Kanellakis5,6, Hannah Ball6,7, Denis C Talbot7, Kevin G Blyth3,8, Nick A Maskell9,2, Ioannis Psallidas5,6.   

Abstract

Malignant pleural mesothelioma is an aggressive malignancy of the pleural surface, predominantly caused by prior asbestos exposure. There is a global epidemic of malignant pleural mesothelioma underway, and incidence rates are predicted to peak in the next few years.This article summarises the epidemiology and pathogenesis of malignant pleural mesothelioma, before describing some key factors in the patient experience and outlining common symptoms. Diagnostic approaches are reviewed, including imaging techniques and the role of various biomarkers. Treatment options are summarised, including the importance of palliative care and methods of controlling pleural effusions. The evidence for chemotherapy, radiotherapy and surgery is reviewed, both in the palliative setting and in the context of trimodality treatment. An algorithm for managing malignant pleural effusion in malignant pleural mesothelioma patients is presented. Finally new treatment developments and novel therapeutic approaches are summarised.
Copyright ©ERS 2016.

Entities:  

Mesh:

Year:  2016        PMID: 27903668     DOI: 10.1183/16000617.0063-2016

Source DB:  PubMed          Journal:  Eur Respir Rev        ISSN: 0905-9180


  77 in total

Review 1.  Dosimetry of inhaled elongate mineral particles in the respiratory tract: The impact of shape factor.

Authors:  Bahman Asgharian; T Price Owen; Eileen D Kuempel; Annie M Jarabek
Journal:  Toxicol Appl Pharmacol       Date:  2018-05-05       Impact factor: 4.219

2.  TAZ activation by Hippo pathway dysregulation induces cytokine gene expression and promotes mesothelial cell transformation.

Authors:  Akihiro Matsushita; Tatsuhiro Sato; Satomi Mukai; Teruaki Fujishita; Emi Mishiro-Sato; Maho Okuda; Masahiro Aoki; Yoshinori Hasegawa; Yoshitaka Sekido
Journal:  Oncogene       Date:  2018-11-06       Impact factor: 9.867

Review 3.  CAR T-cell therapy for lung cancer and malignant pleural mesothelioma.

Authors:  Masha Zeltsman; Jordan Dozier; Erin McGee; Daniel Ngai; Prasad S Adusumilli
Journal:  Transl Res       Date:  2017-04-26       Impact factor: 7.012

4.  Deep learning-based segmentation of malignant pleural mesothelioma tumor on computed tomography scans: application to scans demonstrating pleural effusion.

Authors:  Eyjolfur Gudmundsson; Christopher M Straus; Feng Li; Samuel G Armato
Journal:  J Med Imaging (Bellingham)       Date:  2020-01-29

5.  Early-stage Clinical Characterization of Malignant Pleural Mesothelioma.

Authors:  Yoshiki Negi; Kozo Kuribayashi; Norihiko Funaguchi; Hiroshi Doi; Koji Mikami; Toshiyuki Minami; Teruhisa Takuwa; Takashi Yokoi; Seiki Hasegawa; Takashi Kijima
Journal:  In Vivo       Date:  2018 Sep-Oct       Impact factor: 2.155

Review 6.  Chemotherapy treatment in malignant pleural mesothelioma: a difficult history.

Authors:  Marika Cinausero; Karim Rihawi; Francesca Sperandi; Barbara Melotti; Andrea Ardizzoni
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

Review 7.  Clinical diagnosis of malignant pleural mesothelioma.

Authors:  Andrea Bianco; Tullio Valente; Maria Luisa De Rimini; Giacomo Sica; Alfonso Fiorelli
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

8.  Potential role of serum mesothelin in predicting survival of patients with malignant pleural mesothelioma.

Authors:  Vincenzo Fontana; Maria Pia Pistillo; Antonella Vigani; Pier Aldo Canessa; Giovanni Berisso; Ugo Giannoni; Paola Ferro; Maria Cristiana Franceschini; Roberta Carosio; Marika Tonarelli; Paolo Dessanti; Silvio Roncella
Journal:  Oncol Lett       Date:  2020-12-18       Impact factor: 2.967

9.  Pleurectomy/decortication and hyperthermic intrathoracic chemoperfusion using cisplatin and doxorubicin for malignant pleural mesothelioma.

Authors:  Laura V Klotz; Michael Lindner; Martin E Eichhorn; Uwe Grützner; Ina Koch; Hauke Winter; Teresa Kauke; Thomas Duell; Rudolf A Hatz
Journal:  J Thorac Dis       Date:  2019-05       Impact factor: 2.895

10.  Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma.

Authors:  Giulio Metro; Diego Signorelli; Elio G Pizzutilo; Laura Giannetta; Giulio Cerea; Miriam Garaffa; Alex Friedlaender; Alfredo Addeo; Martina Mandarano; Guido Bellezza; Fausto Roila
Journal:  Hum Vaccin Immunother       Date:  2021-05-18       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.